David A. Ramsay
Known title: DirectorCIK: 0001283292
David A. Ramsay's purchase track record
How the stock did after each of David A. Ramsay's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
18
of 18 since August 17, 2021
Stock higher 6 months later
94%
3 months: 78%
Median 6-month return
+31.2%
3 months: +9.4%
Beat the S&P 500
94%
median +37.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/31/2025 | SVRA | $416K | -17.7% | +27.1% | +18.7% |
| 11/18/2024 | SVRA | $288K | -3.7% | +5.7% | +1.2% |
| 5/24/2023 | SVRA | $259K | +46.5% | +39.6% | +10.7% |
| 12/28/2022 | SVRA | $61K | +35.3% | +80.7% | +15.7% |
| 12/16/2022 | SVRA | $171K | +33.6% | +102.0% | +14.5% |
| 11/17/2022 | SVRA | $97K | +115.3% | +95.4% | +6.4% |
| 9/26/2022 | SVRA | $144K | +11.0% | +49.3% | +8.8% |
| 9/16/2022 | SVRA | $54K | +1.3% | +35.3% | +1.1% |
| 9/7/2022 | SVRA | $44K | +15.1% | +81.3% | +0.3% |
| 8/30/2022 | SVRA | $143K | +17.1% | +78.6% | -0.4% |
| 6/17/2022 | SVRA | $138K | +15.4% | +16.9% | +4.8% |
| 12/29/2021 | SVRA | $64K | +2.4% | +24.2% | -20.3% |
| 12/17/2021 | SVRA | $28K | +10.2% | +10.2% | -20.5% |
| 12/8/2021 | SVRA | $66K | +8.6% | +40.0% | -12.4% |
| 11/30/2021 | SVRA | $67K | +6.5% | +21.3% | -9.5% |
| 11/18/2021 | SVRA | $215K | +5.5% | +26.4% | -17.1% |
| 9/28/2021 | SVRA | $176K | -0.8% | -3.9% | +6.4% |
| 8/17/2021 | SVRA | $115K | -5.1% | +3.4% | +0.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Savara Stock Mentioned Among Gainers in Market Roundup. Savara Inc. was included in a recent market roundup highlighting stocks that moved higher on Wednesday. The company's shares are currently trading near a key support level, which may have contributed to the short-term price movement noted in the report. This mention reflects general market activity rather than a specific corporate announcement.
Transaction History
| HALO | ▲ Buy | Option Exercise | 10,000 | $0 | 6/30/2026 | View on chart |
| HALO | ▼ Sell | Tax Withholding | 5,408 | $423K | 6/30/2026 | View on chart |
| SVRA | ▼ Sell | Open Market | 20,000 | $121K | 12/19/2025 | View on chart |
| SVRA | ▲ Buy | Grant | 40,000 | $0 | 12/9/2025 | View on chart |
| SVRA | ▲ Buy | Open Market | 150,000 | $416K | 3/31/2025 | View on chart |
| SVRA | ▲ Buy | Grant | 40,000 | $0 | 12/12/2024 | View on chart |
| SVRA | ▲ Buy | Open Market | 100,000 | $288K | 11/18/2024 | View on chart |
| SVRA | ▲ Buy | Grant | 22,500 | $0 | 12/14/2023 | View on chart |
| SVRA | ▲ Buy | Open Market | 37,124 | $98K | 5/26/2023 | View on chart |
| SVRA | ▲ Buy | Open Market | 12,876 | $33K | 5/25/2023 | View on chart |
| SVRA | ▲ Buy | Open Market | 50,000 | $128K | 5/24/2023 | View on chart |
| SVRA | ▲ Buy | Open Market | 29,000 | $45K | 12/30/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 7,000 | $11K | 12/29/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 3,293 | $5K | 12/28/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 15,707 | $23K | 12/23/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 41,414 | $61K | 12/22/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 13,830 | $21K | 12/20/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 3,586 | $5K | 12/20/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 40,719 | $61K | 12/19/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 341 | $512 | 12/16/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 4,610 | $7K | 11/23/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 15,495 | $22K | 11/22/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 25,005 | $36K | 11/21/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 16,100 | $22K | 11/18/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 8,900 | $11K | 11/17/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 73,893 | $101K | 9/27/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 31,107 | $43K | 9/26/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 30,000 | $43K | 9/23/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 600 | $870 | 9/20/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 1,400 | $2K | 9/19/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 6,000 | $9K | 9/16/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 29,000 | $41K | 9/8/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 2,130 | $3K | 9/7/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 870 | $1K | 9/6/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 39,768 | $56K | 9/1/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 39,494 | $56K | 8/31/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 20,738 | $29K | 8/30/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 39,000 | $56K | 6/22/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 21,094 | $29K | 6/21/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 39,906 | $53K | 6/17/2022 | View on chart |
| SVRA | ▲ Buy | Open Market | 35,000 | $45K | 12/30/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 15,000 | $19K | 12/29/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 25,000 | $28K | 12/17/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 15,000 | $16K | 12/15/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 35,000 | $36K | 12/10/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 13,157 | $14K | 12/8/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 11,843 | $12K | 12/7/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 21,394 | $23K | 12/2/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 9,000 | $10K | 12/1/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 3,606 | $4K | 12/1/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 16,000 | $17K | 11/30/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 90,000 | $97K | 11/22/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 49,800 | $53K | 11/19/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 60,200 | $65K | 11/18/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 50,000 | $65K | 9/30/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 47,500 | $61K | 9/29/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 39,552 | $51K | 9/28/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 12,948 | $15K | 8/18/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 17,788 | $22K | 8/18/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 66,554 | $78K | 8/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Halozyme Adds Jim Daly to Board Amid Q2 Earnings Review
Halozyme Therapeutics has appointed Jim Daly to its Board of Directors, a move that signals continued focus on governance and long-term strategy. This update arrives alongside a broader market review of the company's Q2 performance relative to other therapeutics firms. The stock is currently trading above its average analyst target price, with recent technical data showing confirmation near key support levels.
Halozyme Adds Jim Daly to Board Amid Q2 Earnings Review. Halozyme Therapeutics has appointed Jim Daly to its Board of Directors, a move that signals continued focus on governance and long-term strategy. This update arrives alongside a broader market review of the company's Q2 performance relative to other therapeutics firms. The stock is currently trading above its average analyst target price, with recent technical data showing confirmation near key support levels.